17 Jun 2016 15:48
Results of AGM
17 June 2016
Silence Therapeutics plc, AIM: SLN, ("Silence" or "the Company"), a leader in the development and delivery of novel RNA therapeutics, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer | Tel: +44 (0)20 3457 6900
|
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel | Tel: +44 (0)20 7523 8350
|
Peel Hunt LLP (Joint Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert | Tel: +44 (0) 20 3727 1000
|
Notes to Editors:
About Silence Therapeutics plc
Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo. We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics.
SLN.L (SLN)